MetaStat Announces Presentations at the Biotech Showcase conference in San Francisco on Monday, January 7, 2013

MONTCLAIR, N.J., Jan. 3, 2013

The presentation schedule is as follows:

Conference: Biotech Showcase 2013
Date: Monday, January 7, 2013
Location: Parc 55 Wyndham
Time: 3:45 P.M. PST

The Company's management team will also be available for separate one-on-one meetings throughout the day Monday and on Tuesday and Wednesday, January 8^th and 9^th.

About MetaStat, Inc.

MetaStat's proprietary technology platform is the result of over 15 years of collaboration involving four scientific/academic institutions, which enabled us to characterize the behavior, mechanics and genetics of metastatic cancer cells.

Our MetaSite Breast™ and MenaCalc™ diagnostic product lines are designed to accurately predict the probability of cancer metastasizing. They are intended to allow clinicians to better "customize" cancer treatment decisions by positively identifying and differentiating high-risk patients who need aggressive therapy and by sparing low-risk patients from the harmful side effects and expense of chemotherapy and radiation therapies. Furthermore, we believe our MenaCalc™ diagnostic platform may be applicable in up to 80% of all solid epithelial cancers, including breast, prostate, lung and colorectal, which account for over 50% of all new cancer cases in the U.S. each year. As such, we believe our diagnostic products represent a significant breakthrough for cancer patients and their doctors because 90% of all solid tumor cancer deaths are due from metastasis.